The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for therapeutic actions

British Journal of Pharmacology

Volumn 138, Issue 4, 2003, Pages 544-553

  Tzavara, Eleni T ^a   Davis, Richard J ^a   Perry, Kenneth W ^a   Li, Xia ^a   Salhoff, Craig ^a   Bymaster, Frank P ^a   Witkin, Jeffrey M ^a   Nomikos, George G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT; ACh; ADHD; Antidepressant; Antipsychotic; DA; Microdialysis; NE; Prefrontal cortex; SR141716A

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CATECHOLAMINE; DEXAMPHETAMINE; DOPAMINE; NEUROLEPTIC AGENT; NORADRENALIN; PHENCYCLIDINE; RIMONABANT; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CATECHOLAMINE RELEASE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; HYPERACTIVITY; IMMOBILIZATION; LOCOMOTION; MALE; MICRODIALYSIS; MONOAMINERGIC SYSTEM; MOOD DISORDER; MOUSE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RAT; SWIMMING; TISSUE DISTRIBUTION; TISSUE LEVEL;

ANIMALS; BIOGENIC MONOAMINES; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PIPERIDINES; PREFRONTAL CORTEX; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SYNAPTIC TRANSMISSION;

EID: 0037294538     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705100     Document Type: Article

References (50)

1. ACQUAS, E., PISANU, A., MARROCU, P. & DI CHIARA, G. (2000). Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur. J. Pharmacol., 401, 179-185.
2. ALONSO, R., VOUTSINOS, B., FOURNIER, M., LABIE, C., STEINBERG, R., SOUILHAC, J., LE FUR, G. & SOUBRIE, P. (1999). Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience, 91, 607-620.
3. ARBORELIUS, L., NOMIKOS, G.G., HACKSELL, U. & SVENSSON, T.H. (1993). (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand., 148, 465-466.
4. AUCLAIR, N., OTANI, S., SOUBRIE, P. & CREPEL, F. (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol., 83, 3287-3293.
5. BAXTER, JR, L.R., SCHWARTZ, J.M., PHELPS, M.E., MAZZIOTTA, J.C., GUZE, B.H., SELIN, C.E., GERNER, R.H. & SUMIDA, R.M. (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry, 46, 243-250.
6. BIEDERMAN, J. & SPENCER, T. (1999). Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry, 46, 1234-1242.
7. BYMASTER, F.P., KATNER, J.S., NELSON, D.L., HEMRICK-LUECKE, S.K., THRELKELD, P.G., HEILIGENSTEIN, J.H., MORIN, S.M., GEHLERT, D.R. & PERRY, K.W. (2002a). Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711.
8. BYMASTER, F.P., ZHANG, W., CARTER, P.A., SHAW, J., CHERNET, E., PHEBUS, L., WONG, D.T. & PERRY, K.W. (2002b). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology, 160, 353-361.
9. CADOGAN, A.K., ALEXANDER, S.P., BOYD, E.A. & KENDALL, D.A. (1997). Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem., 69, 1131-1137.
10. CARLSSON, A., WATERS, N., WATERS, S. & CARLSSON, M.L. (2000). Network interactions in schizophrenia-therapeutic implications. Brain Res. Brain Res. Rev., 31, 342-349.
11. CHAPERON, F. & THIEBOT, M.H. (1999). Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol., 13, 243-281.
12. CHEN, J.P, PAREDES, W., LI, J., SMITH, D., LOWINSON, J. & GARDNER, E.L. (1990). Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology, 102, 156-162.
13. COLOMBO, G., AGABIO, R., FA, M., GUANO, L., LOBINA, C., LOCHE, A., REALI, R. & GESSA, G.L. (1998). Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol., 33, 126-130.
14. DE VRIES, T.J., SHAHAM, Y., HOMBERG, J.R., CROMBAG, H., SCHUURMAN, K., DIEBEN, J., VANDERSCHUREN, L.J. & SCHOFFELMEER, A.N. (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med., 7, 1151-1154.
15. DEUTCH, A.Y., MOGHADDAM, B., INNIS, R.B., KRYSTAL, J.H., AGHAJANIAN, G.K., BUNNEY, B.S. & CHARNEY, D.S. (1991). Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr. Res., 4, 121-156.
16. DI CHIARA, G. (1999). Drug addiction as dopamine-dependent associative learning disorder. Eur. J. Pharmacol., 375, 13-30.
17. DI MARZO, V., GOPARAJU, S.K., WANG, L., LIU, J., BATKAI, S., JARAI, Z., FEZZA, F., MIURA, G.I., PALMITER, R.D., SUGIURA, T. & KUNOS, G. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410, 822-825.
18. FOWLER, C.J. & JACOBSSON, S.O. (2002). Cellular transport of anandamide, 2- arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostaglandins Leukot. Essent. Fatty Acids, 66, 193-200.
19. GERDEMAN, G. & LOVINGER, D.M. (2001). CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol., 85, 468-471.
20. GESSA, G.L., CASU, M.A., CARTA, G. & MASCIA, M.S. (1998). Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur. J. Pharmacol., 355, 119-124.
21. GIFFORD, A.N. & ASHBY, JR., C.R. (1996). Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther., 277, 1431-1436.
22. ICHIKAWA, J., DAI, J., O'LAUGHLIN, I.A., FOWLER, W.L. & MELTZER, H.Y. (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology, 26, 325-339.
23. IMPERATO, A., PUGLISI-ALLEGRA, S., CASOLINI, P. & ANGELUCCI, L. (1991). Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res., 538, 111-117.
24. KATHMANN, M., BAUER, U., SCHLICKER, E. & GOTHERT, M. (1999). Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch. Pharmacol., 359, 466-470.
25. LICHTMAN, A.H. (2000). SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol., 404, 175-179.
26. LICHTMAN, A.H., VARVEL, S.A. & MARTIN, B.R. (2002). Endocannabinoids in cognition and dependence. Prostaglandins Leukot. Essent. Fatty Acids, 66, 269-285.
27. LINNER, L., ENDERSZ, H., OHMAN, D., BENGTSSON, F., SCHALLING, M. & SVENSSON, T.H. (2001). Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Pharmacol. Exp. Ther., 297, 540-546.
28. LUCKI, I. (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol., 8, 523-532.
29. MAS-NIETO, M., POMMIER, B., TZAVARA, E.T., CANEPARO, A., DA NASCIMENTO, S., LE FUR, G., ROQUES, B.P. & NOBLE, F. (2001). Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br. J. Pharmacol., 132, 1809-1816.
30. MASSERANO, J.M., KAROUM, F. & WYATT, R.J. (1999). SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of d-amphetamine and apomorphine. Behav. Pharmacol., 10, 429-432.
31. MCGAUGHY, J., DALLEY, J.W., MORRISON, C.H., EVERITT, B.J. & ROBBINS, T.W. (2002). Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. J. Neurosci., 22, 1905-1913.
32. MEYER-LINDENBERG, A., MILETICH, R.S., KOHN, P.D., ESPOSITO, G., CARSON, R.E., QUARANTELLI, M., WEINBERGER, D.R. & BERMAN, K.F. (2002). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci., 5, 267-271.
33. MOOR, E., SCHIRM, E., JACSO, J. & WESTERINK, B.H. (1998). Effects of neostigmine and atropine on basal and handling-induced acetylcholine output from ventral hippocampus. Neuroscience, 82, 819-825.
34. NOMIKOS, G.G., IURLO, M., ANDERSSON, J.L., KIMURA, K. & SVENSSON, T.H. (1994). Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology, 115, 147-156.
35. PAXINOS, G. & WATSON, C. (1986). The rat brain in stereotaxic coordinates. San Diego: Academic Press.
36. PERRY, K.W. & FULLER, R.W. (1997). Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J. Neural. Transm., 104, 953-966.
37. PIOMELLI, D., GIUFFRIDA, A., CALIGNANO, A. & RODRIGUEZ DE FONSECA, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218-224.
38. PONCELET, M., BARNOUIN, M.C., BRELIERE, J.C., LE FUR, G. & SOUBRIE, P. (1999). Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology, 144, 144-150.
39. PORSOLT, R.D., BERTIN, A. & JALFRE, M. (1977). Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie, 229, 327-336.
40. RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G., CAPUT, D., FERRARA, P., SOUBRIE, P., BRELIERE, J.C. & LE FUR, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
41. ROBERTSON, G.S, MATSUMURA, H. & FIBIGER, H.C. (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther., 271, 1058-1066.
42. SANTUCCI, V., STORME, J.J., SOUBRIE, P. & LE FUR, G. (1996). Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci., 58, PL103-110.
43. SCHLICKER, E. & KATHMANN, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 22, 565-572.
44. SHIRAZI-SOUTHALL, S., RODRIGUEZ, D.E., NOMIKOS & G.G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology, 26, 583-594.
45. SZABO, B., MULLER, T. & KOCH, H. (1999). Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J. Neurochem., 73, 1084-1089.
46. TANDA, G., CARBONI, E., FRAU, R. & DI CHIARA, G. (1994). Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology, 115, 285-288.
47. TERRANOVA, J.P., STORME, J.J., LAFON, N., PERIO, A., RINALDI-CARMONA, M., LE FUR, G. & SOUBRIE, P. (1996). Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology, 126, 165-172.
48. TZAVARA, E.T., PERRY, K.W., RODRIGUEZ, D.E., BYMASTER, F.P. & NOMIKOS, G.G. (2001). The cannabinoid CB(1) receptor antagonist SRI41716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur. J. Pharmacol., 426, R3-4.
49. WESTERINK, B.H., KAWAHARA, Y., DE BOER, P., GEELS, C., DE VRIES, JB., WIKSTROM, H.V., VAN KALKEREN, A., VAN VLIET, B., KRUSE, C.G. & LONG, S.K. (2001). Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol., 412, 127-138.
50. ZHANG, W., PERRY, K.W., WONG, D.T., POTTS, B.D., BAO, J., TOLLEFSON, G.D. & BYMASTER, F.P. (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 23, 250-262.